These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25274258)

  • 1. Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice?
    Dranitsaris G; Papadopoulos G
    Appl Health Econ Health Policy; 2015 Jun; 13(3):291-302. PubMed ID: 25274258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care cost containment strategies used in four other high-income countries hold lessons for the United States.
    Stabile M; Thomson S; Allin S; Boyle S; Busse R; Chevreul K; Marchildon G; Mossialos E
    Health Aff (Millwood); 2013 Apr; 32(4):643-52. PubMed ID: 23569043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy.
    Bentley C; Peacock S; Abelson J; Burgess MM; Demers-Payette O; Longstaff H; Tripp L; Lavis JN; Wilson MG
    Health Res Policy Syst; 2019 Feb; 17(1):17. PubMed ID: 30732616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in cancer therapeutics and patient access to new drugs.
    Dranitsaris G; Truter I; Lubbe MS; Amir E; Evans W
    Pharmacoeconomics; 2011 Mar; 29(3):213-24. PubMed ID: 21184619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in cancer drug assessment between Spain and the United Kingdom.
    Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
    Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles.
    Rand LZ; Kesselheim AS
    J Law Med Ethics; 2020 Sep; 48(3):583-594. PubMed ID: 33021189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International diffusion of new health technologies: a ten-country analysis of six health technologies.
    Packer C; Simpson S; Stevens A;
    Int J Technol Assess Health Care; 2006; 22(4):419-28. PubMed ID: 16984674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care technology as a policy issue.
    Banta HD
    Health Policy; 1994; 30(1-3):1-21. PubMed ID: 10139487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey.
    Tordrup D; Angelis A; Kanavos P
    Appl Health Econ Health Policy; 2013 Dec; 11(6):639-52. PubMed ID: 24129648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quality of health care in Germany. A six-country comparison].
    Sawicki PT
    Med Klin (Munich); 2005 Nov; 100(11):755-68. PubMed ID: 16328186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access, affordability, and insurance complexity are often worse in the United States compared to ten other countries.
    Schoen C; Osborn R; Squires D; Doty MM
    Health Aff (Millwood); 2013 Dec; 32(12):2205-15. PubMed ID: 24226092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inequities in access to medical care in five countries: findings from the 2001 Commonwealth Fund International Health Policy Survey.
    Schoen C; Doty MM
    Health Policy; 2004 Mar; 67(3):309-22. PubMed ID: 15036818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient access to new cancer drugs in the United States and Australia.
    Wilson A; Cohen J
    Value Health; 2011; 14(6):944-52. PubMed ID: 21914517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription drug accessibility and affordability in the United States and abroad.
    Morgan S; Kennedy J
    Issue Brief (Commonw Fund); 2010 Jun; 89():1-12. PubMed ID: 20614652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rising cost of anticancer drugs in Australia.
    Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
    Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
    MacLeod TE; Harris AH; Mahal A
    Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.